Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRIEF
June 27, 2005
- 20 New Kit Products Added to NHI Price List
June 27, 2005
- Half of Glaucoma Patients Lack Subjective Symptoms: Survey
June 27, 2005
- FPMAJ Announces Its 2005 Report on NHI Pricing
June 27, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 27, 2005
- Gov't Approves 2005 White Paper on Aging Society
June 27, 2005
- MEDICAL DEVICE NEWS IN BRIEF
June 27, 2005
- Generic Substitution Only Speculation at This Point: Mr Futagawa
June 27, 2005
- REGULATORY NEWS IN BRIEF
June 27, 2005
- Chugai to Establish New Strategic Marketing Unit in July
June 27, 2005
- Healthnet to Enter Chinese Market with NDA Support Business
June 27, 2005
- Mattson Jack Group to Strengthen Support in Field of Oncology
June 27, 2005
- Takeda Leads Image Ranking among Clinicians: Nikkei BP Survey
June 27, 2005
- BUSINESS NEWS IN BRIEF
June 27, 2005
- NEW PRODUCTS
June 27, 2005
- Consolidated Sales Up 0.8% for 26 Listed Pharma Companies in FY2004
June 20, 2005
- R&D NEWS IN BRIEF
June 20, 2005
- Non-consolidated Sales of 28 Listed JPMA Companies Up 0.8% to \4,184,156 Mil.
June 20, 2005
- 20% of Hepatitis C Patients Untreated Despite Diagnosis
June 20, 2005
- AstraZeneca, Shionogi Conducting Crestor PMS According to ICH E2E
June 20, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…